切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2014, Vol. 03 ›› Issue (02) : 91 -94. doi: 10.3877/cma.j.issn.2095-3224.2014.02.04

所属专题: 文献

青年专家论坛

不可切除的结直肠癌肝转移灶局部治疗进展
郑鹏1, 任黎1,()   
  1. 1. 200032 上海,复旦大学中山医院普外科
  • 收稿日期:2014-03-07 出版日期:2014-04-25
  • 通信作者: 任黎
  • 基金资助:
    上海市科委启明星计划(12QA1400600)

Advances in local treatment of unresectable liver metastasis from colorectal cancer

Peng ZHENG1, Li REN1,()   

  1. 1. General Surgery of Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • Received:2014-03-07 Published:2014-04-25
  • Corresponding author: Li REN
  • About author:
    Corresponding author: REN Li, Email:
引用本文:

郑鹏, 任黎. 不可切除的结直肠癌肝转移灶局部治疗进展[J]. 中华结直肠疾病电子杂志, 2014, 03(02): 91-94.

Peng ZHENG, Li REN. Advances in local treatment of unresectable liver metastasis from colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2014, 03(02): 91-94.

肝脏是结直肠癌发生转移最主要的靶器官,手术切除是治疗肝转移最理想的方式,但对于不可切除的肝转移,局部控制是治疗的首要目标,在全身化疗的基础上,局部治疗发挥了重要的强化和补充作用。目前常用的局部治疗方式包括消融治疗、肝脏导向化疗、放射治疗等。近年来这些方式在低毒副作用、高可重复性、长期控制等方向均有一定的进展。

Liver is the most common metastasis organ of colorectal caner.For recectable CLMs(colorectal liver metastasis), radical resection is the optimal choice, whereas, for unresectable ones, local control is the priority.Local treatments significantly enhance or complement the systematic chemotherapy, which is worldwide standard-of-care for unresectable CLMs.Nowadays, Local treatments consist of thermal ablation, liver-oriented chemotherapy, radiotherapy and so on.There have achieved many breakthroughs, making local treatments less poisoning, highly repeatable and able to get longtime control.

[1]
Pathak S,Jones R,Tang JM,et al:Ablative therapies for colorectal liver metastases:A systematic review.Colorectal Dis,2011,13:252-265.
[2]
Ruers T,Punt C,Van Coevorden F,et al.Radiofrequency ablation combined with systemic treatment versus systemic treatment alone inpatients with non-resectable colorectal liver metastases:a randomized EORTC Intergroup phase II study(EORTC 40004).Ann Oncol,2012,23:2619-2626.
[3]
Evrard S,Rivoire M,Arnaud J,et al.Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection.Br J Surg,2012,99:558-565.
[4]
Schullian P,Weiss H,Klaus A,et al.Laparoscopic liver packing to protect surrounding organs during thermal ablation.Minim Invasive Ther Allied Technol,2014.
[5]
Thanos L,Mylona S,Galani P,et al.Overcoming the heat-sink phenomenon:successful radiofrequency thermal ablation of liver tumors in contact with blood vessels.Diagn Interv Radiol,2008,14(1):51-56.
[6]
Jones RP,Kitteringham NR,Terlizzo M,et al.Microwave ablation of ex vivo human liver and colorectal liver metastases with a novel 14.5 GHz generator.Int J Hyperthermia,2012,28(1):43-54.
[7]
Schuld J,Richter S,Oberkircher LW,et al.Evidence for tumor cell spread during local hepatic ablation of colorectal liver metastases.J Surg Res,2012,178(1):268-279.
[8]
Orsi F,Zhang L,Arnone P,et al.High-intensity focused ultrasound ablation:effective and safe therapy for solid tumors in difficult locations.AJR Am J Roentgenol,2010,195(3):W245-252.
[9]
Elias D,Baton O,Sideris L,et al.Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases.J Surg Oncol,2005,90:36-42.
[10]
Livraghi T,Solbiati L,Meloni F,et al.Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection:the "test-of-time approach" .Cancer,2003,97:3027-3035.
[11]
Mocellin S,Pilati P,Lise M,et al.Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer:the end of an era? J Clin Oncol,2007,25:5649–5654.
[12]
Kemeny NE,Melendez FD,Capanu M,et al.Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.J Clin Oncol,2009,27:3465–3471.
[13]
Albert M,Kiefer M,Sun W,et al.Chemoembolization of colorectal liver metastases with cisplatin,doxorubicin,mitomycin C,ethiodol,and polyvinyl alcohol.Cancer,2011,117(2):343-352.
[14]
Fiorentini G,Aliberti C,Tilli M,et al.Intra-arterial infusion of irinotecan-loaded drug-eluting beads(DEBIRI)versus intravenous therapy(FOLFIRI)for hepatic metastases from colorectal cancer:Final results of a phase III study.Anticancer Res,2012,32:1387-1396.
[15]
Engels.Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer.Radiation Oncology,2012,7:34.
[16]
Young Seok Seo,Mi-Sook Kim,Hyung-Jun Yoo,et al.Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.World J Gastroenterol,2014,20(8):2005-2013.
[17]
Sofocleous CT,Garcia AR,Pandit-Taskar N,et al.Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.Clin Colorectal Cancer,2014,13(1):27-36.
[18]
Vente MAD,Wondergem M,Tweel I,et al.Yttrium-90 microsphere radioembolization for the treatment of liver malignancies:a structured meta-analysis.European Radiology,2009,19(4):951–959.
[19]
Hipps D,Ausania F,Manas DM,et al.Selective Interarterial Radiation Therapy(SIRT)in Colorectal Liver Metastases:How Do We Monitor Response?HPB Surgery,2013,1-10.
[20]
王锡山.从ESMO共识看结直肠癌肝转移的治疗策略.中华结直肠疾病电子杂志,2014,3(1):9-11.
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[3] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[4] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[5] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[6] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[7] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[8] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[9] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[10] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[11] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[12] 黄怡诚, 陆晨, 孙司正, 喻春钊. 肝特异性转录因子FOXA2在人结直肠癌肝转移阶梯模型中的表达变化及其意义[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 396-403.
[13] 刘祺, 张凯, 李建男, 刘铜军. 结直肠癌肝转移生物治疗的现状及进展[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 415-419.
[14] 吴寅, 陈智琴, 高勇, 权明. Her-2阳性结直肠癌的诊治进展[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 420-425.
[15] 范博洋, 王宁, 张骞, 王贵玉. 结直肠癌转移调控的环状RNA分子机制研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 426-430.
阅读次数
全文


摘要